Determination of platinum drug release and liposome stability in human plasma by CE-ICP-MS

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Determination of platinum drug release and liposome stability in human plasma by CE-ICP-MS. / Nguyen, Trinh Thi Nhu Tam; Ostergaard, Jesper; Stürup, Stefan; Gammelgaard, Bente.

In: International Journal of Pharmaceutics, Vol. 449, No. 1-2, 05.06.2013, p. 95-102.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Nguyen, TTNT, Ostergaard, J, Stürup, S & Gammelgaard, B 2013, 'Determination of platinum drug release and liposome stability in human plasma by CE-ICP-MS', International Journal of Pharmaceutics, vol. 449, no. 1-2, pp. 95-102. https://doi.org/10.1016/j.ijpharm.2013.03.055

APA

Nguyen, T. T. N. T., Ostergaard, J., Stürup, S., & Gammelgaard, B. (2013). Determination of platinum drug release and liposome stability in human plasma by CE-ICP-MS. International Journal of Pharmaceutics, 449(1-2), 95-102. https://doi.org/10.1016/j.ijpharm.2013.03.055

Vancouver

Nguyen TTNT, Ostergaard J, Stürup S, Gammelgaard B. Determination of platinum drug release and liposome stability in human plasma by CE-ICP-MS. International Journal of Pharmaceutics. 2013 Jun 5;449(1-2):95-102. https://doi.org/10.1016/j.ijpharm.2013.03.055

Author

Nguyen, Trinh Thi Nhu Tam ; Ostergaard, Jesper ; Stürup, Stefan ; Gammelgaard, Bente. / Determination of platinum drug release and liposome stability in human plasma by CE-ICP-MS. In: International Journal of Pharmaceutics. 2013 ; Vol. 449, No. 1-2. pp. 95-102.

Bibtex

@article{9a8e4f1768dd450c9087cbfe131ee1f1,
title = "Determination of platinum drug release and liposome stability in human plasma by CE-ICP-MS",
abstract = "An in vitro method for simultaneous assessment of platinum release and liposome stability of liposomal formulations in human plasma is demonstrated. The development and assessment of the method was performed on a PEGylated liposomal formulation containing cisplatin. Complete separation of free cisplatin, encapsulated cisplatin and cisplatin bound to plasma components was achieved by capillary electrophoresis (CE) separation and simultaneous monitoring of phosphorous (phospholipid) and platinum (cisplatin) by inductively coupled plasma mass spectrometry (ICP-MS). The method allows assessment of the encapsulation efficiency of the formulation, the physical stability of liposomes as well as cisplatin leakage in human plasma. The method was applied for studying the disintegration of liposomes and the interactions of leaked cisplatin with plasma components. Triggered release of the drug into plasma by sonication was also demonstrated. Analysis of liposomal formulations with alternative phospholipid compositions containing oxaliplatin showed similar results. Thus, the present in vitro method is suitable for mimicking the in vivo drug release profile in human plasma after administration of liposomal platinum formulations to patients. This approach may be of use in early drug development as well as in quality control.",
author = "Nguyen, {Trinh Thi Nhu Tam} and Jesper Ostergaard and Stefan St{\"u}rup and Bente Gammelgaard",
note = "Copyright {\textcopyright} 2013 Elsevier B.V. All rights reserved.",
year = "2013",
month = jun,
day = "5",
doi = "10.1016/j.ijpharm.2013.03.055",
language = "English",
volume = "449",
pages = "95--102",
journal = "International Journal of Pharmaceutics",
issn = "0378-5173",
publisher = "Elsevier",
number = "1-2",

}

RIS

TY - JOUR

T1 - Determination of platinum drug release and liposome stability in human plasma by CE-ICP-MS

AU - Nguyen, Trinh Thi Nhu Tam

AU - Ostergaard, Jesper

AU - Stürup, Stefan

AU - Gammelgaard, Bente

N1 - Copyright © 2013 Elsevier B.V. All rights reserved.

PY - 2013/6/5

Y1 - 2013/6/5

N2 - An in vitro method for simultaneous assessment of platinum release and liposome stability of liposomal formulations in human plasma is demonstrated. The development and assessment of the method was performed on a PEGylated liposomal formulation containing cisplatin. Complete separation of free cisplatin, encapsulated cisplatin and cisplatin bound to plasma components was achieved by capillary electrophoresis (CE) separation and simultaneous monitoring of phosphorous (phospholipid) and platinum (cisplatin) by inductively coupled plasma mass spectrometry (ICP-MS). The method allows assessment of the encapsulation efficiency of the formulation, the physical stability of liposomes as well as cisplatin leakage in human plasma. The method was applied for studying the disintegration of liposomes and the interactions of leaked cisplatin with plasma components. Triggered release of the drug into plasma by sonication was also demonstrated. Analysis of liposomal formulations with alternative phospholipid compositions containing oxaliplatin showed similar results. Thus, the present in vitro method is suitable for mimicking the in vivo drug release profile in human plasma after administration of liposomal platinum formulations to patients. This approach may be of use in early drug development as well as in quality control.

AB - An in vitro method for simultaneous assessment of platinum release and liposome stability of liposomal formulations in human plasma is demonstrated. The development and assessment of the method was performed on a PEGylated liposomal formulation containing cisplatin. Complete separation of free cisplatin, encapsulated cisplatin and cisplatin bound to plasma components was achieved by capillary electrophoresis (CE) separation and simultaneous monitoring of phosphorous (phospholipid) and platinum (cisplatin) by inductively coupled plasma mass spectrometry (ICP-MS). The method allows assessment of the encapsulation efficiency of the formulation, the physical stability of liposomes as well as cisplatin leakage in human plasma. The method was applied for studying the disintegration of liposomes and the interactions of leaked cisplatin with plasma components. Triggered release of the drug into plasma by sonication was also demonstrated. Analysis of liposomal formulations with alternative phospholipid compositions containing oxaliplatin showed similar results. Thus, the present in vitro method is suitable for mimicking the in vivo drug release profile in human plasma after administration of liposomal platinum formulations to patients. This approach may be of use in early drug development as well as in quality control.

U2 - 10.1016/j.ijpharm.2013.03.055

DO - 10.1016/j.ijpharm.2013.03.055

M3 - Journal article

C2 - 23583709

VL - 449

SP - 95

EP - 102

JO - International Journal of Pharmaceutics

JF - International Journal of Pharmaceutics

SN - 0378-5173

IS - 1-2

ER -

ID: 45760641